Annexon (ANNX) awards 250,000 options and RSUs to EVP & CSO

Rhea-AI Filing Summary

Annexon, Inc. reported that EVP & Chief Scientific Officer Dean Richard Artis acquired equity awards on February 19, 2026. He received a stock option for 250,000 shares at an exercise price of $0.00 per share and 62,500 restricted stock units. The RSUs vest one-third each year on February 19, beginning in 2027, while 1/48 of the option vests monthly from February 19, 2026, becoming fully vested on the fourth anniversary, subject to his continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ARTIS DEAN RICHARD

Role EVP & CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	--
Grant/Award	Common Stock	62,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 shares (Direct); Common Stock — 185,987 shares (Direct)

Footnotes (1)

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARTIS DEAN RICHARD

(Last) (First) (Middle)

C/O ANNEXON, INC.

1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		62,500(1)	A	$0	185,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.1	02/19/2026		A		250,000		(2)	02/19/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

2. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Jennifer Lew, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Annexon (ANNX) report for Dean Richard Artis?

Annexon (ANNX) reported that EVP & Chief Scientific Officer Dean Richard Artis received equity awards on February 19, 2026. He was granted 250,000 stock options at $0.00 per share and 62,500 restricted stock units, all subject to time-based vesting and continued service.

How many Annexon (ANNX) stock options were granted to Dean Richard Artis?

Dean Richard Artis was granted stock options covering 250,000 shares of Annexon common stock. These options vest in equal monthly installments of 1/48 each month from February 19, 2026, becoming fully vested on the fourth anniversary, contingent on his continuous service with Annexon.

What is the vesting schedule for Dean Richard Artis’s Annexon (ANNX) RSUs?

The equity grant includes restricted stock units representing 62,500 shares of Annexon common stock. One-third of these RSUs vest each year on February 19, starting on February 19, 2027, provided Dean Richard Artis continues his service with Annexon on each applicable vesting date.

How many Annexon (ANNX) shares does Dean Richard Artis own after this Form 4?

Following the reported award of 62,500 restricted stock units, Dean Richard Artis holds 185,987 shares of Annexon common stock directly. He also holds an option to purchase 250,000 additional shares, which vest over four years, subject to his ongoing service with the company.

Is the Annexon (ANNX) Form 4 a stock purchase or an equity award?

The Annexon Form 4 reflects an equity award, not an open-market stock purchase. Dean Richard Artis received a grant of 250,000 stock options at a $0.00 exercise price and 62,500 restricted stock units, both subject to specified time-based vesting conditions tied to continued employment.